Financial News

Bristol-Myers will not pursue accelerated approval

Bristol-Myers Squibb Co. (NYSE: BMY) will not pursue accelerated approval for its lung cancer treatment Opdivo sending the stock price plummeting $6.26 to close at $49.23.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback